Drug makers’ REMS misuse costs $13.4bn per year: report
06-09-2018
FDA’s Gottlieb launches biosimilars action plan
19-07-2018
USFDA to modernise generic review with $37.6m funding
19-06-2018
BIO 2018: Allergan-tribe deal just the start, says former USPTO director
08-06-2018